Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study

Results

Title:	Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study
Authors:	Davies, Andrew J; Mihaljevic, Biljana S ; Mercadal, Santiago; Mihaylov, Georgi; Leppa, Sirpa; Cotting, Denise; Veenstra, Klaas; Zharkov, Artem; Dixon, Mark; Barrett, Martin; Macdonald, David;
Issue Date:	2016
Publication:	BLOOD
ISSN:	0006-4971 Blood Search Idenfier
Type:	Conference Paper
Collation:	vol. 128 br. 22 str. 1103-1103
DOI:	10.1182/blood.V128.22.1103.1103
WoS-ID:	000394446803129
URI:	https://enauka.gov.rs/handle/123456789/821029
Project:	Takeda Pharmaceutical Company Ltd <it>Mundipharma</it> GSKGlaxoSmithKline Karyopharma Roche Holding Gilead Sciences Bayer AG Pfizer JanssenJohnson & Johnson USAJanssen Biotech Inc Mundipharma CTI Bio Pharma
Metadata source:	(Preuzeto iz Nasi u WoS)
M-category:	Mp. category will be shown later

1
OpenCitations

Altmetric

Dimensions

Unpaywall

Google Scholar^TM